Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12405329 | 0.85 | KDM1A (0.41) | MAOAMAOBCHRNB4CHRNA3KDM1A | |
| SCHEMBL14592022 | 0.84 | MEN1 (0.41) | MAOAMAOBMEN1GAAKMT2A | |
| SCHEMBL5206019 | 0.84 | MEN1 (0.41) | MAOAMAOBMEN1GAAKMT2A | |
| SCHEMBL30290975 | 0.84 | MEN1 (0.41) | MAOAMAOBMEN1GAAKMT2A | |
| SCHEMBL24819998 | 0.81 | MEN1 (0.38) | MAOAMAOBCHRNB4CHRNA3MEN1 | |
| SCHEMBL3077728 | 0.81 | SLC6A2 (0.48) | MAOAMAOBMEN1GAAKMT2A | |
| SCHEMBL5114374 | 0.81 | SLC6A2 (0.48) | MAOAMAOBMEN1GAAKMT2A | |
| SCHEMBL5114376 | 0.81 | SLC6A2 (0.48) | MAOAMAOBMEN1GAAKMT2A | |
| SCHEMBL3077730 | 0.81 | SLC6A2 (0.48) | MAOAMAOBMEN1GAAKMT2A | |
| SCHEMBL24822696 | 0.81 | MEN1 (0.38) | MAOAMAOBCHRNB4CHRNA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024010785-A1 | KETOREDUCTASE ENZYMES FOR THE SYNTHESIS OF 1,3-DIOL SUBSTITUTED INDANES | MERCK SHARP & DOHME LLC (US) | 2024-01-11 | — | — | WO | disclosed |
| CN-108292064-A | Alignment films and liquid crystal display device | 夏普株式会社 | 2018-07-17 | — | — | CN | disclosed |
| CN-104903363-B | Monomer, liquid-crystal composition, the manufacture method of liquid crystal display device and liquid crystal display device | 夏普株式会社 | 2018-05-04 | — | — | CN | disclosed |
| CN-106873248-A | Liquid crystal display panel and liquid crystal display device | 夏普株式会社 | 2017-06-20 | — | — | CN | disclosed |
| CN-106662767-A | Liquid-crystal display | 夏普株式会社 | 2017-05-10 | — | — | CN | disclosed |
| CN-103765305-B | Liquid crystal display panel and liquid crystal display device | 夏普株式会社 | 2017-04-12 | — | — | CN | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-7205324-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1127054-A4 | NOVEL INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2006-11-02 | — | — | EP | disclosed |
| US-7060720-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB CO. (US) | 2006-06-13 | — | — | US | disclosed |
| US-6617323-B2 | For therapy and prophylaxis of transplant rejection and autoimmune diseases | BRISTOL-MYERS SQUIBB CO. | 2003-09-09 | — | — | US | disclosed |
| US-20020183315-A1 | Amino-substituted compounds useful as inhibitors of impdh enzyme | IWANOWICZ EDWIN J (US) | 2002-12-05 | — | — | US | disclosed |
| US-6420403-B1 | INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE, TRANSPLANT REJECTION AND AUTOIMMUNE DISEASES. | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-16 | — | — | US | disclosed |
| EP-1127054-A1 | NOVEL INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000026197-A9 | NOVEL INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000026197-A1 | NOVEL INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-11 | — | — | WO | disclosed |
| EP-0664478-A2 | Silver-carboxylate/1,2-diazine compounds as silver sources in photothermographic and thermographic elements | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-07-26 | — | — | EP | disclosed |
| US-5061605-A | IMPROVED SENSITIVITY TO LONG WAVELENGTHS | FUJI PHOTO FILM CO., LTD. (JP) | 1991-10-29 | — | — | US | disclosed |
| US-4078934-A | Photosensitive, image-forming composition containing a leuco 2,3-disubstituted-1-indanone and a photooxidant | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-03-14 | — | — | US | disclosed |
| US-3992450-A | PHOTOSENSITIVE COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | MAOA 3505/4885MAOB 3220/4885CHRNB4 4734/4885 |
| US-20020183315-A1 | Amino-substituted compounds useful as inhibitors of impdh enzyme | IMPDH1, IMPDH2, ALDH7A1 | MAOA 255/4885MAOB 104/4885CHRNB4 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.